BEDSIDE TESTING OF CYP2C19 GENOTYPE TO GUIDE ANTIPLATELET THERAPY: IMPLEMENTATION IN THE CATHETERIZATION LABORATORY

Although FDA recommended pharmacogenetic testing and alternative antiplatelet agents in CYP2C19 loss-of-function(LoF) allele carriers in patients treated with clopidogrel, implementation in practice has been minimal. Appropriate P2Y12 receptor antagonist therapy following PCI based on bedside